Anavex Life Sciences (NASDAQ:AVXL – Get Free Report) and Legend Biotech (NASDAQ:LEGN – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations and institutional ownership.
Institutional & Insider Ownership
31.6% of Anavex Life Sciences shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 11.4% of Anavex Life Sciences shares are held by insiders. Comparatively, 0.0% of Legend Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Anavex Life Sciences and Legend Biotech, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Anavex Life Sciences | 1 | 1 | 2 | 0 | 2.25 |
| Legend Biotech | 1 | 3 | 11 | 0 | 2.67 |
Profitability
This table compares Anavex Life Sciences and Legend Biotech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Anavex Life Sciences | N/A | -38.76% | -35.01% |
| Legend Biotech | -28.86% | -21.93% | -13.21% |
Risk & Volatility
Anavex Life Sciences has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.08, meaning that its share price is 92% less volatile than the S&P 500.
Valuation & Earnings
This table compares Anavex Life Sciences and Legend Biotech”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Anavex Life Sciences | N/A | N/A | -$46.38 million | ($0.46) | -6.41 |
| Legend Biotech | $1.03 billion | 3.26 | -$296.80 million | ($0.80) | -22.70 |
Anavex Life Sciences has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Anavex Life Sciences, indicating that it is currently the more affordable of the two stocks.
Summary
Anavex Life Sciences beats Legend Biotech on 7 of the 13 factors compared between the two stocks.
About Anavex Life Sciences
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
About Legend Biotech
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
